撤下抗疟药奎尼丁:伦理考量
2017年礼来公司宣布停产奎尼丁,当时该药是美国FDA唯一批准用于重症疟疾的治疗药物。此举使危重患者和医生无法获得标准治疗,并造成获取救命疗法的危险延误。文章探讨了营利性公司在利益冲突下的伦理义务,以及医疗系统缺乏可执行的问责与监管如何使单一企业行为削弱系统伦理,并提出修订生产合同、加速必要疗法监管审批和建立多学科咨询机构等干预措施。
要点
- 奎尼丁停产使美国重症疟疾患者失去唯一FDA批准的标准治疗。
- 缺乏可执行的问责与监管使单一企业行为得以削弱医疗系统伦理。
- 建议修订生产合同、加速必要疗法审批并建立多学科咨询机构。
核心结论
- 营利性公司停产必需药物可导致患者无法获得伦理医疗,需建立 proactive、协作且可执行的机制。
研究设计与样本
- 本文为伦理分析文章,未报告系统检索范围或样本量。
主要发现
- 2017年礼来公司宣布停产奎尼丁,当时该药是美国FDA唯一批准用于重症疟疾的治疗药物。
- 停产决定使危重患者和医生无法获得标准治疗,并造成获取救命疗法的危险延误。
- 医疗系统缺乏可执行的问责与监管,使单一企业行为在无反对情况下削弱系统伦理。
临床怎么用
- 临床医生应关注必需药物供应中断风险,并参与机构层面预警与替代方案准备。
局限性
- 本文为伦理分析,未提供定量研究数据或系统评价方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2017, the pharmaceutical company Eli Lilly announced it would stop manufacturing quinidine, the only Food and Drug Administration-approved treatment for severe malaria in the United States at the time. This decision left critically ill patients and their providers without access to the standard of care and created dangerous delays in obtaining life-saving therapy. As providing access to essential medications and minimizing preventable harm are fundamental aspects of ethical healthcare, Eli Lilly's action effectively prevented the delivery of ethical care to patients across the country. This case raises urgent and essential questions regarding the ethical obligations of a for-profit company when faced with conflicting interests and the ability of the broader healthcare community-including government agencies, hospital systems, and professional societies-to safeguard ethical patient care. We examined how the absence of enforceable accountability and oversight throughout the healthcare system allowed the actions of a single corporate entity to undermine the system's ethics without opposition. We propose interventions including amended production contracts, expedited regulatory approval of essential therapies, and the development of multidisciplinary advisory bodies to promote and protect the delivery of ethical care. As such conflicts will inevitably recur, proactive, collaborative, and enforceable mechanisms that center ethical patient care are urgently needed.
引用
- Craft JF, Openshaw JJ, Travassos PM, et al. Pulling the Drug Out From Underneath: Ethical Considerations in the Discontinuation of the Antimalarial Quinidine. Clin Infect Dis. 2026. PMID: 40576352. doi:10.1093/cid/ciaf271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。